An investigation has linked the risk of overactive urinary bladder (VH) as a side effect of cholinesterase inhibitor drugs (ChEI) that are taken for dementia and Alzheimer's disease .
The study, published in the journal ' Journal of the American Geriatrics Society' and collected by EuropaPress, has been based on the thesis work of the first author of the study, Prajakta Masurkar. ChEI medications, including donepezil, galantamine, and rivastigmine, increase communication between nerve cells to improve cognition .
«The study found that the risk of overactive bladder varies between individual ChEIs. Using a national cohort of older adults with dementia, we also found that donepezil was associated with a thirteen percent increased risk of overactive bladder OAB compared to rivastigmine, while there was no differential risk of OAB with galantamine and rivastigmine “, has stated the professor of Pharmacy Rajender Aparasu.
For the study, we examined 524. 975 adults (of 65 years or more) with dementia who were ChEI users (donepezil 80, 72%, rivastigmine 16, 41%, galantamine 2, 87%). The primary outcome of interest was the diagnosis of OAB or the prescription of antimuscarinics, drugs that help correct the overactive urinary bladder , within six months after the start of the ChEI.
“The findings suggest the need to understand and control drug-related morbidity in older adults with dementia,” Aparasu stressed.